Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
Quick Take Taysha Gene Therapies ( TSHA ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing genetic therapy treatments for various neurodegenerative diseases and other disorders. TSHA is still at a precl...
Quick Take Virios Therapeutics ( VIRI ) has filed to raise $34.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a drug treatment for fibromyalgia, a nerve pain condition. VIRI has generated interesting early stage efficacy r...
The following slide deck was published by Novartis AG in conjunction with this Read more ...
BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...
Background - Liking the setup Novo Nordisk ( NVO ) is trading at a 23X TTM P/E. This is below that of the S&P 500 ( SPY ) - of which it cannot be a member as a Danish company - which is now at 24X peak (CY 2019) GAAP EPS of $139, and a much higher P/E based on current earnings. Unlike mo...
Genomic medicine, the next major biotech era, is primarily pre-commercial though a few medicines have been approved. The list of FDA-approved cellular and gene therapy products did increase in July when the second Kite Pharma ( GILD ) cell therapy - Tecartus - was approved for relapsed/refract...
This article is part of a series that provides an ongoing analysis of the changes made to Tweedy Browne’s 13F portfolio on a quarterly basis. It is based on Tweedy Browne’s regulatory 13F Form filed on 08/11/2020. Please visit our Tracking Tweedy Browne Portfolio series to ge...
The art of medicine consists of amusing the patient while nature cures the disease. ― Voltaire At first glance, Tekla World Healthcare Fund ( THW ) looks like a solid dividend bet because it has been paying dividends consistently since inception and it sports an attractive dividend ...
Original post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Quick Take Checkmate Pharmaceuticals ( CMPI ) intends to raise $75 million from the sale of its common stock stock in an IPO, according to an amended registration statement . The company is advancing a biologic particle treatment for melanomas and head & neck squamous cell carcinomas....
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...